Table 1 Clinicopathologic background according to the disease status

Median age, years (IQR)

62 (51.5–71)

62 (42–70)

62 (52.5–71)

0.68^a

Sex, n (%)

0.57^b

 Men

15 (65 %)

7 (78 %)

8 (57 %)

 Women

8 (35 %)

2 (22 %)

6 (43 %)

Follow-up, months (IQR)

30 (18–51.5)

19 (18–33)

30.5 (24–87.5)

0.12^a

Tumor size, mm (IQR)

77 (50–210)

80 (50–120)

75 (51–112)

0.99^a

Symptoms positive, n (%)

0.87^b

 Yes

12 (52 %)

4 (44 %)

8 (57 %)

 No

11 (48 %)

5 (56 %)

6 (43 %)

Infiltration into the adjacent organs, n (%)

0.01*^,b

 Yes

11 (48 %)

1 (11 %)

10 (71 %)

 No

12 (52 %)

8 (89 %)

4 (29 %)

Margins, n (%)

0.94^b

 R0

4 (17 %)

2 (22 %)

2 (14 %)

 R1

17 (74 %)

6 (67 %)

11 (79 %)

 R2

2 (9 %)

1 (11 %)

1 (7 %)

Histological type, n (%)

0.87^b

 Liposarcoma

12 (52 %)

4 (44 %)

8 (57 %)

 Leiomyosarcoma

4 (17 %)

2 (22 %)

2 (14 %)

 MFH

3 (14 %)

1 (11 %)

2 (14 %)

 Other

4 (17 %)

2 (22 %)

2 (14 %)

Tumor grade, n (%)

0.82^b

 Grade 1

3 (14 %)

1 (11 %)

2 (14 %)

 Grade 2

4 (17 %)

2 (22 %)

2 (14 %)

 Grade 3

16 (69 %)

6 (67 %)

10 (71 %)

Necrosis, n (%)

0.88^b

 Yes

17 (74 %)

7 (78 %)

10 (71 %)

 No

6 (26 %)

2 (22 %)

4 (29 %)

Mitosis, n (%)

0.61^b

 1–9/10HPF

14 (61 %)

5 (56 %)

9 (64 %)

 10–20/HPF

9 (39 %)

4 (44 %)

5 (36 %)

Ki-67 LI, n (%)

0.42^b

 <25 %

13 (56 %)

4 (44 %)

9 (64 %)

 ≥25 %

10 (44 %)

5 (56 %)

5 (36 %)